REPAIR study findings outline the benefits of macitentan for right ventricular functioning in pulmonary arterial hypertension. Results of the REPAIR (Right vEntricular remodeling in Pulmonary ArterIal ...

FDA approved macitentan/tadalafil (Opsynvi) as the first single-tablet combination therapy targeting multiple pathways for pulmonary arterial hypertension (PAH), Johnson & Johnson announced. The fixed ...

Patients with pulmonary arterial hypertension (PAH) taking spironolactone saw a reduced risk of morbidity and mortality when receiving macitentan 10 mg. Research presented at CHEST 2021 showed that ...

Macitentan significantly reduced the risk of morbidity and mortality by 45% versus placebo Macitentan reduced the risk of PAH-related death or hospitalization by 50% The presentation from Professor ...

Lungs Heart Janssen noted that the phase 3 UNISUS study will continue as planned. Janssen has decided to stop a phase 3 study evaluating macitentan 75mg for the treatment of chronic thromboembolic ...

Please provide your email address to receive an email when new articles are posted on . Macitentan showed no new safety signals in patients with pulmonary arterial hypertension from two real-world ...

Please provide your email address to receive an email when new articles are posted on . A prior study found that a combination macitentan and tadalafil tablet increased 6-minute walk distance at 16 ...

In March, we reported on back-to-back FDA approvals for two treatments in pulmonary arterial hypertension (PAH). In this report, we follow up on what has happened since. After the FDA approved both ...

The study found no significant differences between the groups in terms of disease progression, morbidity or mortality, or all-cause death. Macitentan demonstrated superiority over other endothelin ...

ATLANTA — Macitentan significantly reduced morbidity and mortality in patients with pulmonary arterial hypertension (PAH), according to findings from the phase 3 SERAPHIN trial. Lewis Rubin, MD, from ...

Apotex appealed the trial decision, finding that Apo-Macitentan would infringe Canadian Patent No. 2,659,770 (770 Patent). Even though Apotex would only sell Apo-Macitentan by itself, the Federal ...

In a public decision dated July 6, 2022 in an action under the Patented Medicines (Notice of Compliance) Regulations, Justice Pallotta of the Federal Court found that Apotex would infringe Janssen’s ...